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Abstract Tamoxifen has been a standard ﬁrst-line
endocrine therapy for post-menopausal women with
hormone-responsive advanced breast cancer, but more
than half of patients fail to respond and time to pro-
gression is less than 12 months in responders. The
third-generation aromatase inhibitors were developed
to provide more effective alternatives to tamoxifen. In
the Femara Study PO25, post-menopausal women with
advanced breast cancer were randomized to receive
letrozole 2.5 mg (n = 453) or tamoxifen 20 mg
(n = 454) given orally daily until progressive disease
occurred. Patients were permitted to cross over to the
other treatment at progression. In the primary efﬁcacy
analysis, median time to progression (TTP) was sig-
niﬁcantly longer with letrozole than with tamoxifen
(9.4 months vs. 6.0 months, respectively; P < 0.0001).
The objective response rate (ORR) was signiﬁcantly
higher for letrozole than for tamoxifen (32% vs. 21%;
P = 0.0002). Prospectively planned analyses of the
intent-to-treat population showed that letrozole sig-
niﬁcantly improved overall survival (OS) compared
with tamoxifen over the ﬁrst 24 months of the trial. An
exploratory analysis of patients, who did not cross over,
indicated a median OS beneﬁt of 14 months for
letrozole compared with tamoxifen. Letrozole is the
only third-generation aromatase inhibitor that has
demonstrated signiﬁcant improvements in ORR, TTP,
and early OS.
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Introduction and rationale
The treatment goals for advanced or metastatic breast
cancer (MBC) are to delay disease progression and to
prolong survival [1, 2] and to optimize patient care in
terms of ameliorating symptoms, thereby improving
or maintaining quality of life [3–5]. Although treat-
ment may include surgery and radiation therapy for
the treatment of locally advanced tumors or isolated
metastases, systemic therapies (endocrine, cytotoxic,
biologic, and palliative) are the foundation of disease
management [6, 7]. Systemic therapy for patients with
advanced breast cancer should be tailored according
to speciﬁc tumor biology, particularly with respect to
hormone receptor (HR) and human epidermal growth
factor receptor 2 (HER2) status, the growth rate of
disease, presence of visceral metastases, history of
prior therapy and response, susceptibility to treat-
ment-related toxicity, and individual patient prefer-
ence [7–14]. Systemic therapy can prolong survival
and enhance patient quality of life but is not curative
[1]. Consequently, minimally toxic endocrine thera-
pies are generally preferred to cytotoxic therapy as
initial therapy for patients with hormone-responsive
tumors [6, 15].
Since the 1980s, endocrine therapy with tamoxifen
was well established as a standard ﬁrst-line treatment
for post-menopausal women with advanced breast
cancer, even though estrogen receptor (ER) expression
was not always used routinely to select patients for
endocrine therapy [16–18]. The ﬁrst-generation
H. T. Mouridsen (&)
Department of Oncology, Rigshospitalet, Copenhagen
University Hospital, Blegdamsvej 9, 2100 Copenhagen,
Denmark
e-mail: hmouridsen@rh.dk
123
Breast Cancer Res Treat (2007) 105:19–29
DOI 10.1007/s10549-007-9527-6aromatase inhibitor aminoglutethimide or a progestin
such as megestrol acetate has provided a reasonable
second-line alternative [19–22]. The objective response
rate (ORR) to tamoxifen was shown to be in the range
of 25%–45% [16, 17, 19, 21, 23–32], indicating that
more than half of the patients with advanced breast
cancer are intrinsically resistant to tamoxifen. Fur-
thermore, the short median time to treatment failure
(TTF), in the range 6–8 months, demonstrates a rela-
tively rapid emergence of resistance in patients initially
sensitive to tamoxifen [19, 27]. Loss of ER expression
appears to be the dominant mechanism of de novo
resistance, and most ER/progesterone receptor nega-
tive (PgR–) tumors do not respond to tamoxifen
[18, 33–36]. However, the majority of patients who
develop acquired tamoxifen resistance still express ER
at the time of progression [37, 38] and may respond to
alternative endocrine therapies [39].
The third-generation aromatase inhibitors letrozole,
anastrozole, and exemestane were developed in the
search for more effective therapeutic alternatives to
tamoxifen. Aromatase inhibitors prevent estrogen
synthesis by potently inhibiting the aromatase enzyme,
which converts androgens to estrogen [40]. Unlike
tamoxifen, the aromatase inhibitors do not have any
partial estrogen-agonist activity [41] and are less sus-
ceptible to the emergence of resistance associated with
long-term estrogen deprivation [42]. The development
and mechanism of action of aromatase inhibitors is
described in detail in the article by Dr. Bhatnagar in
this supplement.
Studies of aromatase inhibitors in the second-line
setting
The initial randomized controlled trials of third-gen-
eration aromatase inhibitors were conducted in pa-
tients with advanced breast cancer in whom tamoxifen
had failed (i.e., second-line setting). Letrozole, anas-
trozole, and exemestane all demonstrated evidence of
clinical superiority to megestrol acetate in the second-
line setting [43–47]. Thus, the individual trials dem-
onstrate a trend or even a signiﬁcant difference in favor
of the third-generation aromatase inhibitors in one or
more efﬁcacy end points; in addition, the aromatase
inhibitors were shown to be associated with improved
tolerability versus comparator endocrine therapy in
these randomized trials.
One trial demonstrated a signiﬁcantly higher ORR
for letrozole (2.5 mg dose) compared with megestrol
acetate (24% vs. 16%, respectively; P = 0.04) and a
trend toward longer time to progression (5.6 vs.
5.1 months, P = 0.07) [45]. In this trial, low-dose
letrozole (0.5 mg) was associated with similar efﬁcacy
outcomes compared with megestrol acetate. However,
in another similarly designed trial with letrozole versus
megestrol acetate, overall response rates with the two
doses of letrozole (0.5 and 2.5 mg) and with the com-
parator were similar (21%, 16%, and 15%, respec-
tively). In this trial, low-dose letrozole was superior to
megestrol acetate in terms of time to progression
(TTP) (P = 0.044) and survival (P = 0.053). Differ-
ences in the distribution of baseline variables may ex-
plain the different outcomes in the two trials in terms
of the superiority of letrozole over megestrol acetate
according to dose [48]. Letrozole was signiﬁcantly
better tolerated than megestrol acetate, speciﬁcally in
terms of serious adverse experiences, discontinuation
due to poor tolerability, cardiovascular side effects,
and weight gain [45].
Third-generation aromatase inhibitors have dem-
onstrated greater potency and selectivity than the ﬁrst-
generation compound aminoglutethimide [49]. Two
doses of the most potent aromatase inhibitor letrozole
(2.5 mg and 0.5 mg) [49] were compared with amino-
glutethimide in a randomized controlled trial in the
second-line setting and demonstrated superior efﬁcacy
and improved safety [50]. The higher dose of letrozole
showed a trend (P = 0.06) toward superior ORR
(19.5%) compared with aminoglutethimide (12.4%).
Letrozole 2.5 mg was also signiﬁcantly superior in
TTP, TTF, and overall survival (OS). Fewer patients
taking letrozole experienced adverse events than those
taking aminoglutethimide (33% vs. 46%) [50]. Le-
trozole has also been compared with anastrozole in a
randomized, unblinded trial in the second-line setting
in patients with MBC. The trial showed that letrozole
was associated with a statistically higher ORR than
anastrozole (19.1% vs. 12.3%, respectively; P = 0.013),
whereas TTP (the major end point), TTF, and clinical
beneﬁt and duration of response were similar between
the two agents [51]. Both letrozole and anastrozole
were well tolerated, and a similar incidence of adverse
events was observed in the two groups.
These studies generated the hypothesis that letrozole
might have superior efﬁcacy to tamoxifen as ﬁrst-line
therapy for advanced breast cancer. A large clinical
trial (Femara Study PO25) was therefore conducted to
compare the efﬁcacy and tolerability of letrozole with
those of tamoxifen as ﬁrst-line therapy in post-meno-
pausal women with advanced breast cancer [52]. This
review will describe the results of the PO25 trial,
highlighting the evidence for the superiority of letroz-
ole over tamoxifen as ﬁrst-line endocrine therapy in
this setting.
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The Femara Study PO25 was the largest phase 3 trial
conducted in the advanced breast cancer setting [52,
53]. This randomized, double-blind, double-dummy
trial was powered for superiority and needed to enroll
approximately 900 patients to demonstrate a 20%
reduction in the risk of progression with the more
effective treatment. To achieve the recruitment target,
the trial was conducted in 201 centers in 29 countries.
Local ethics review boards approved the protocol, and
all patients gave written informed consent before study
enrollment.
Randomized trial design
Patients were randomized to receive letrozole 2.5 mg
or tamoxifen 20 mg given orally daily until progressive
disease occurred. Patients were permitted to cross over
from 1 treatment arm to the other in a double-blind
fashion if their ﬁrst-line treatment was discontinued
because of progressive disease or for any other reason
(Fig. 1). Patients in whom endocrine therapy was dis-
continued were subsequently treated as clinically
indicated, using chemotherapy, trastuzumab, and bis-
phosphonates. The crossover design was an integral
part of the study, and it probably affected the assess-
ment of OS.
Patient population
Post-menopausal women with advanced breast cancer,
deﬁned as stage IIIB locally advanced disease,
locoregionally recurrent disease that was not amenable
to surgery or radiotherapy, or metastatic disease, were
eligible for inclusion in the trial. All patients presented
with measurable or assessable tumors and were can-
didates for endocrine therapy. Patients had estrogen
receptor-positive (ER+) and/or progesterone receptor-
positive (PgR+) tumors or unknown HR status. One
prior chemotherapy regimen for the treatment of
metastatic disease was permitted, but recurrence dur-
ing or within 12 months of adjuvant antiestrogen
therapy and any prior endocrine therapy for advanced
breast cancer precluded enrollment.
End points
The primary end point was TTP, deﬁned as the interval
between date of randomization and the earliest date of
disease progression. Disease progression was deter-
mined on the basis of tumor progression (an increase
of 25% or more in measurable lesions, an estimated
increase of the same magnitude of nonmeasurable le-
sions, or the appearance of new lesions), treatment
discontinuation with evidence of clinical deterioration
due to breast cancer, death due to breast cancer, or
death of unknown cause (with documented evidence of
clinical deterioration due to breast cancer) while
receiving treatment or within 6 weeks of discontinua-
tion of treatment.
The secondary end points were ORR, duration of
overall response, rate and duration of clinical beneﬁt,
TTF, time to response (TTR), time to chemotherapy
(TTC), safety, and OS. ORR was deﬁned as the pro-
portion of patients who achieved a complete response
(CR) or a partial response (PR), conﬁrmed by a second
evaluation 1–3 months later. The duration of overall
response was deﬁned for patients with CR or PR, as
the interval between date of randomization and the
earliest date of disease progression. The rate of clinical
beneﬁt was deﬁned as proportion of patients who
achieved CR or PR or who stabilized (NC) for at least
24 weeks; the duration of clinical beneﬁt was deﬁned
for patients who achieved CR or PR or NC as the
interval between date of randomization and the earli-
est date of disease progression. TTF was deﬁned as the
interval between date of randomization and the earli-
est date of disease progression, withdrawal, lost to
follow-up, or death. TTR was deﬁned for CR or PR
Randomization
N = 907
Tamoxifen
20 mg
(n = 454)
Letrozole
2.5 mg
(n = 453)
Tamoxifen
(n = 239)
Letrozole
(n = 228)
Post-endocrine
treatments (i.e.
chemotherapy,
trastuzumab,
bisphosphonates,
etc)
3.5 years 1.5 years
Fig. 1 Study design
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123patients as the interval between randomization and the
earliest documentation of response, and TTC was de-
ﬁned as the total duration of endocrine therapy. The
duration of OS was deﬁned as the interval between
randomization and death for any reason.
Exploratory analyses of OS were performed. The
ﬁrst analysis included all patients with censoring at
crossover, whereas the second included only patients
with no crossover. The latter group predominantly
comprised of patients with ‘‘nonresponsive’’ disease
(patients who responded to ﬁrst-line therapy are more
likely to be crossed over later at progression), whereas
the former included ‘‘nonresponsive’’ as well as
‘‘responsive’’ patients.
Efﬁcacy
The characteristics of the 907 patients included in the
intent-to-treat (ITT) population were well balanced
between the letrozole and tamoxifen arms. The median
age of the patients was 65 years (range 31–96 years) in
the letrozole arm and 64 years (range 31–93 years) in
the tamoxifen arm. Patients were predominantly white
(86%), and 92% had Karnofsky performance status
(KPS) scores of 80–100. The majority (93%) of the
study population had metastatic disease. Soft tissue
lesions were the dominant metastatic site in one
quarter of patients and were present in 63% and 61%
of patients in the letrozole and tamoxifen arms,
respectively. Bone metastases were the dominant
metastatic site in approximately 30% of patients and
were present in 54% and 50%, respectively. Visceral
metastases were the dominant site in 43% of patients
in the letrozole arm and 46% of the patients in the
tamoxifen arm. Most patients (71% in the letrozole
arm and 66% in the tamoxifen arm) had not received
any prior chemotherapy, and few had received che-
motherapy for advanced disease (9% and 11%,
respectively). The majority of patients (109 of 167)
treated with adjuvant tamoxifen received at least
2 years of therapy, and the treatment-free interval
between stopping adjuvant therapy and entering the
study was more than 2 years in 126 of 167 patients. Of
the 907 patients included in the ITT efﬁcacy popula-
tion, 467 crossed over to the other treatment arm, 75
continued on ﬁrst-line therapy without progression,
and the remainder terminated ﬁrst-line treatment
without crossover (Fig. 2).
Letrozole was superior to tamoxifen for all primary
and secondary efﬁcacy end points, including a pro-
spectively planned survival analysis at 1- and 2-year
follow-up [53].
Time to progression
In the primary efﬁcacy analysis, the median TTP was
signiﬁcantly longer with letrozole than with tamoxifen
Enrolled
(N = 939)
Crossed over to
tamoxifen
(n = 239)
Disease progression
(n = 233)
Reasons other than
disease progression
(n = 6)
On first-line therapy without
progression (n = 48)
ITT population
(n = 907)
Randomized to letrozole or
tamoxifen (n = 916)
Allocated to
letrozole + tamoxifen excluded
(n = 23)
Letrozole
(n = 458)
Tamoxifen
(n = 458) Excluded (2 from GCP
non-compliant site;
3 did not have active
advanced breast
cancer)
Efficacy population
(n = 453)
Efficacy population
(n = 454)
Excluded (2 from GCP
non-compliant site;
2 did not have active
advanced breast
cancer)
On first-line therapy without
progression (n = 27)
Terminated first-line
treatment without
crossing over
(n = 162)
Crossed over to
letrozole
(n = 228)
Disease progression
(n = 226)
Reasons other than
disease progression
(n = 2)
Terminated first-line
treatment without
crossing over
(n = 199)
Fig. 2 Patient disposition
22 Breast Cancer Res Treat (2007) 105:19–29
123(9.4 months vs. 6.0 months, respectively; P < 0.0001)
(Fig. 3)[ 53]. Of patients in the letrozole arm, 359
(79%) progressed, compared with 387 (85%) in the
tamoxifen arm. The hazard ratio of 0.72 represents a
28% reduction in the risk of disease progression with
letrozole (P = 0.0001).
The signiﬁcant improvement in TTP with letrozole
was conﬁrmed in supportive multivariate analysis of
prospectively deﬁned baseline covariates, including
receptor status, prior adjuvant tamoxifen therapy, and
dominant site of metastatic disease [52, 54]. The anal-
ysis showed that the risk of progression was increased
by the presence of either visceral or bone metastases as
the dominant site of metastatic disease compared with
soft tissue as dominant site. In the multivariate analy-
sis, the signiﬁcant improvement in TTP with letrozole
over tamoxifen (hazard ratio 0.70; 95% conﬁdence
intervals [CI] 0.60, 0.81; P = 0.0001) was similar to the
beneﬁt observed in unadjusted analysis and was sig-
niﬁcant for each individual covariate (P = 0.0001) [53].
Median TTP values for letrozole and tamoxifen in the
different subgroups are shown in Table 1. In patients
with nonvisceral metastases, the risk for progression
was 25% lower with letrozole than with tamoxifen,
whereas in patients with visceral metastases, excluding
the liver, the risk for progression was 34% lower and
the median TTP was almost twice as long with letroz-
ole than with tamoxifen [54]. Although TTP was
shortest for patients with liver lesions, the risk for
progression was still 36% lower with letrozole than
with tamoxifen in this subgroup [54].
Patients with prior adjuvant antiestrogen therapy
beneﬁted from letrozole in line with the total group, as
did patients irrespective of positive or unknown
receptor status of the primary tumor.
A prospectively planned analysis by patient age
(<70 years and ‡70 years) also demonstrated that
median TTP was signiﬁcantly longer for letrozole than
for tamoxifen in both age groups (8.8 months vs.
6.0 months, respectively, in the younger group and
12.2 months vs. 5.8 months in the older group) [55].
Response to therapy
Letrozole was associated with a signiﬁcantly better
response to therapy compared with tamoxifen [52, 53].
ORR was signiﬁcantly higher for letrozole than for
tamoxifen (32% vs. 21%; P = 0.0002), and the corre-
sponding rate of CRs was also signiﬁcantly higher for
letrozole (9% vs. 3%; P = 0.0004). The rate of treat-
ment failure was lower with letrozole (75%) than with
tamoxifen (85%), and median TTF was signiﬁcantly
prolonged (9.0 months vs. 5.7 months, respectively;
P < 0.0001).
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Fig. 3 Time to progression at median follow-up of 32 months for
patients on ﬁrst-line letrozole versus tamoxifen. Reprinted from
ref. [53] with permission from the American Society of Clinical
Oncology
Table 1 Time to progression
in different patient subgroups
[57]
TTP, time to progression; CI,
conﬁdence interval; HR,
hormone receptor
a Hazard ratios \ 1.0
indicate superiority for
letrozole relative to
tamoxifen
Subgroup Letrozole Tamoxifen
Dominant disease site: soft tissue n 113 115
Median TTP 12.1 months 6.4 months
Dominant disease site: bone n 145 131
Median TTP 9.5 months 6.3 months
Dominant disease site: viscera n 195 208
Median TTP 8.3 months 4.6 months
Patients who had n 94 83
received prior Median TTP 8.9 months 5.9 months
antiestrogen Hazard ratio (95% CI)
a 0.60 (0.43, 0.84)
HR-positive n 294 305
Median TTP 9.4 months 6.0 months
Hazard ratio (95% CI)
a 0.69 (0.58, 0.83)
HR-unknown n 159 149
Median TTP 9.2 months 6.0 months
Hazard ratio (95% CI)
a 0.77 (0.60, 0.99)
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for the same covariates as used for the TTP analysis,
showed that prior adjuvant tamoxifen, as well as vis-
ceral or bone metastases as the dominant site of
metastases, signiﬁcantly decreased the probability of
achieving a response. The analysis also conﬁrmed that
letrozole signiﬁcantly increased the probability of
achieving a CR or PR compared with tamoxifen (odds
ratio 1.80, 95% CI 1.32–2.47; P = 0.0002) and that the
superiority of letrozole remained statistically signiﬁ-
cant for each of covariates (P = 0.001) [52]. ORRs
achieved with letrozole and tamoxifen in the different
subgroups are shown in Table 2.
Overall survival
The median OS was 34 months for the letrozole group
and 30 months for the tamoxifen group (P = 0.53).
Prospectively planned analyses of the ITT population
showed that letrozole signiﬁcantly improved OS com-
pared with tamoxifen over the ﬁrst 24 months of the
trial [53]. A Kolmogorov-Smirnov analysis to compare
the survival distributions in the 2 arms [56] demonstrated
a signiﬁcant difference in favor of letrozole between 6
and 20 months (P = 0.003) and showed that the maxi-
mum difference in survival occurred at 14 months; at
this time point, there were 85 deaths (19%) in the le-
trozole arm compared with 132 deaths (29%) in the
tamoxifen arm. In addition, repeated log-rank tests
performed at 6-month intervals indicated that survival
was signiﬁcantly greater with letrozole between 6 and
24 months (6 months: P = 0.0167; 12 months:
P = 0.0038; 18 months: P = 0.0010; 24 months:
P = 0.0246) (Fig. 4). The OS curves for the letrozole
and tamoxifen groups crossed at around 36 months, at
which time point most patients had either crossed over
to the other study drug or had switched to different
second-line treatments [53].
Additional exploratory analyses were therefore
performed to determine the inﬂuence of crossover on
OS. The crossover design was an integral part of the
trial and, as with all crossover designs, had a con-
Table 2 Objective response
rate in different patient
subgroups [57]
ORR, objective response
rate; CI, conﬁdence interval;
HR, hormone receptor
a Odds ratios [1.0 indicate
superiority for letrozole
relative to tamoxifen
Subgroup Letrozole Tamoxifen
Dominant disease site: soft tissue n 113 115
ORR 50% 34%
Dominant disease site: bone n 145 131
ORR 23% 15%
Dominant disease site: viscera n 195 208
ORR 28% 17%
Patients who had n 84 83
received prior ORR 26% 8%
antiestrogen Odds ratio (95% CI)
a
3.85 (1.50, 9.60)
HR-positive n 294 305
ORR 33% 22%
Odds ratio (95% CI)
a
1.78 (1.20, 2.60)
HR-unknown n 159 149
ORR 30% 20%
Odds ratio (95% CI)
a
1.79 (1.10, 3.00)
0.02 0.001 0.004 0.02 p value
58 65 75 89 Tamoxifen
64 75 83 93 Letrozole
24 mo 18 mo 12 mo 6 mo
Patients alive at
6-month intervals (%)
60 54 48 0 6 12 18 24 30 36 42
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Fig. 4 Letrozole versus
tamoxifen: patients alive at
6-month intervals. Reprinted
from ref. [48] with permission
from Elsevier
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123founding inﬂuence on the assessment of OS. Second-
line endocrine therapy is generally less effective than
ﬁrst-line treatment in patients responsive to ﬁrst-line
therapy [16]; therefore, evaluation of OS may be
impaired if the second-line treatment is actually more
effective than the original ﬁrst-line treatment. Fur-
thermore, patients who are responsive to ﬁrst-line
therapy are more likely to cross over than are patients
with nonresponsive disease who do not obtain beneﬁt
from ﬁrst-line therapy.
Approximately 50% of patients crossed over to the
other treatment arm (Fig. 2), and almost all of the
crossovershadoccurredby36 months.Themediantime
tocrossoverwas longerforpatients initiallyrandomized
to the letrozole arm (17 months for letrozole to tamox-
ifen vs. 13 months for tamoxifen to letrozole). The
medianOSfrominitialrandomization,censoringtimeto
death at crossover, was 42 months (95% CI 36 months
to not estimable) for letrozole and 30 months (95% CI
27 to <36 months) for tamoxifen [53]. The superior
efﬁcacy of letrozole compared with tamoxifen was also
indicated by an analysis of mortality rates and OS fol-
lowingcrossovertothealternatetreatment.Theanalysis
showedthatthemortalityratewassubstantiallyreduced
(47% vs. 63%, respectively), and OS improved in pa-
tients who crossed over to second-line letrozole com-
pared with those who crossed over to second-line
tamoxifen (31 months; 95% CI 22–40 months vs.
19 months; 95% CI 17–24 months, respectively) [53].
This OS analysis included all patients censored at
the time of crossover (i.e., both ‘‘nonresponsive’’ and
‘‘responsive’’ patients). A second exploratory efﬁcacy
analysis of OS included only patients who did not cross
over to the other arm and thus predominantly
comprised patients with nonresponsive disease. This
second analysis, limited to the patients who did not
cross over to the alternate drug at progression,
indicated a median OS beneﬁt of 14 months for
letrozole (35 months; 95% CI 29–43 months) com-
pared with tamoxifen (20 months; 95% CI
16–26 months) [57].
Time to chemotherapy
Hormone therapy is the preferred treatment strategy
for patients with hormone-responsive advanced breast
cancer, except for those individuals with rapidly pro-
gressive disease for whom initial chemotherapy is
indicated [15]. Extending the TTC is thus an important
goal with hormone therapy and can maintain quality of
life without having a detrimental effect on outcome. In
the PO25 trial, TTC was signiﬁcantly longer for pa-
tients whose initial treatment was letrozole compared
with those initially randomized to receive tamoxifen
(16.3 vs. 9.3 months; P = 0.005).
Safety
Both letrozole and tamoxifen were well tolerated [52,
53]. The incidence of adverse effects related to study
drug during ﬁrst-line treatment was similar for letroz-
ole (38%) and tamoxifen (37%). Hot ﬂushes (16% and
13%, respectively), nausea (6% and 6%, respectively),
and hair thinning (5% and 3%, respectively) were the
most common treatment-related adverse events re-
ported. Bone fractures of any etiology occurred in
5.3% of patients in the letrozole group, compared with
4.2% in the tamoxifen arm, resulting in fracture rates
per patient-year of treatment of 0.0427 and 0.0451,
respectively [52].
A quality-adjusted time without symptoms or tox-
icity (Q-TWiST) follow-up study assessed the trade-
offs between progression-free survival and toxicity in
the ITT population from the PO25 trial [58]. The
Q-TWiST approach quantitatively adjusts periods in
which treatment toxicities or symptoms of disease
progression are present to reﬂect the potentially re-
duced value for the patient; this methodology divides
the survival time of the patient into various health
states, assigns utility states to each, and compares
treatments based on OS experience [59]. The Q-
TWiST analysis of the clinical trial data from the PO25
trial showed that the longer TTP with letrozole com-
pared with tamoxifen is achieved without increased
time with adverse events (2.2 vs. 2 months, respec-
tively), resulting in a signiﬁcantly greater quality-ad-
justed survival for patients on letrozole (2.5-month
advantage; P < 0.0001) [58].
Time to worsening of KPS (decrease of ‡20 points)
was signiﬁcantly delayed for ﬁrst-line letrozole com-
pared with ﬁrst-line tamoxifen (hazard ratio 0.62;
P = 0.001) [54]. A subset analysis according to sites of
metastases demonstrated that in patients with visceral
metastases without liver involvement (mostly lung
metastases), signiﬁcantly fewer letrozole patients
(14%) than tamoxifen patients (30%) experienced
deteriorations in their KPS scores by ‡20 points [54].
However, KPS was relatively insensitive to change in
these ﬁrst-line patients.
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In addition to its clinical superiority over tamoxifen,
economic analyses have also shown that letrozole is
highly cost-effective as ﬁrst-line endocrine therapy in
post-menopausal women with advanced breast cancer
[60–62]. A follow-up analysis of patient data from the
PO25 trial calculated the cost-effectiveness of ﬁrst-line
letrozole and tamoxifen by determining the ratio: dif-
ference in costs of breast cancer care to the difference
in life years (LYs) between the two treatments [60].
The mean costs of care were $7323 and $5468 for le-
trozole and tamoxifen, respectively, representing $1855
in incremental costs with ﬁrst-line letrozole. Mean LYs
to death or to the end of ﬁrst- or second-line hormonal
therapy were 1.54 and 1.29 for patients randomized to
ﬁrst-line letrozole or tamoxifen, respectively. Thus, the
incremental cost per LY saved with ﬁrst-line letrozole
vs. tamoxifen was $7420 (1855/0.25 = 7420) (2.5–97.5
percentiles $6470–$14,865).
In another economic analysis conducted in the
United Kingdom, data from the PO25 trial were used
to estimate the effectiveness of treatment [61]. The
analysis showed that the mean cost of providing ﬁrst-
and second-line hormonal therapy was GBP4765 for
ﬁrst-line letrozole and GBP3418 for ﬁrst-line tamoxi-
fen (a difference of GBP1347). Since patients receiving
ﬁrst-line letrozole gain an additional 0.228 LYs, or
0.158 quality-adjusted life years (QALYs), the cost-
effectiveness analysis showed that ﬁrst-line hormonal
therapy with letrozole gains additional LYs at a cost of
GBP5917, whereas the cost per additional QALY
gained is GBP8514, which is well within the accepted
cost range.
The PO25 trial data were also used in a Canadian
analysis that compared the cost-effectiveness of
letrozole, anastrozole, and tamoxifen [62]. The analysis
showed an incremental cost per quality-adjusted pro-
gression-free year of CAN$12,500 and CAN$19,600 for
letrozole and anastrozole, respectively, relative to
tamoxifen. The authors concluded that both letrozole
and anastrozole are economically acceptable alterna-
tives to tamoxifen.
Conclusions
The Femara Study PO25 has provided evidence from a
well-powered, randomized, controlled trial to show
that letrozole provides a signiﬁcant advantage in OS
compared with tamoxifen as ﬁrst-line treatment of
patients with advanced breast cancer [53]. Letrozole is
the only aromatase inhibitor to demonstrate consistent
superiority over tamoxifen in this setting [53, 54].
Randomized ﬁrst-line therapy trials of anastrozole,
as part of the TARGET study [63–66], and exemestane
in the EORTC study [67, 68] have provided evidence
of clinical equivalence or superiority to tamoxifen in
post-menopausal women with advanced breast cancer.
However, none of these trials demonstrated statisti-
cally signiﬁcant improvements in all three end points
(ORR, TTP, and OS) for the aromatase inhibitor
compared with tamoxifen. The PO25 study was the
largest of these randomized trials in the ﬁrst-line set-
ting and demonstrated extremely strong clinical bene-
ﬁts, evidenced by signiﬁcant superiority in TTP and
ORR, with letrozole compared with tamoxifen as ﬁrst-
line hormone therapy. The beneﬁts of letrozole were
observed in all patient subgroups, deﬁned by prior
antiestrogen therapy, dominant site of metastatic dis-
ease, HR status (positive or unknown), and age
[52–55]. Furthermore, letrozole is the only aromatase
inhibitor associated with an OS advantage for the ﬁrst-
line setting indication at 1-year and 2-year follow-up
[53]. As demonstrated in the exploratory analysis of
patients who did not cross over to the alternative
treatment arm, letrozole prolonged OS by 14 months
compared with tamoxifen. Thus, for every 100 patients
treated with hormone therapy, eight more will be alive
at 1 year if they receive letrozole instead of tamoxifen.
In conclusion, third-generation aromatase inhibitors
are effective and well tolerated. Letrozole should be
considered as the ﬁrst-line endocrine treatment in post-
menopausal women with hormone-sensitive advanced
or MBC. Of the available agents, only letrozole has
demonstrated signiﬁcant improvements in ORR, TTP,
and early OS.
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